BUZZ-ResMed, Inspire Medical fall after Lilly's weight-loss drug succeeds in sleep apnea trials

Reuters04-17

** Shares of ResMed , Inspire Medical fall premarket after Eli Lilly's weight-loss drug succeeds in trials testing it in sleep apnea patients

** ResMed shares down 6.6% to 172.60, Inspire Medical stock falls 7.7% to $204.50

** Lilly's weight-loss drug helped cut frequency of irregular breathing in patients with obstructive sleep apnea by as much as 63% on average across two late-stage trials

** LLY shares up 1.2% to $755.72

** ResMed and Inspire Medical make medical devices used to treat sleep apnea, a potentially serious sleep disorder in which breathing repeatedly stops and starts

** As of last close, RMD shares up 7.5% YTD, INSP up ~9%

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment